# Accelerate Diagnostics Inc. (AXDX)

Source: https://www.quantisnow.com/company/AXDX
Generated: 2026-11-10T00:06:28.131Z

- Ticker: AXDX
- Exchange: NASDAQ
- Sector: Industrials
- Industry: Biotechnology: Laboratory Analytical Instruments
- Website: acceleratediagnostics.com

## About

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.

## Latest AXDX news and filings

- 2025-05-28 20:10 UTC [SEC Form 8-K] [Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/accelerate-diagnostics-inc-filed-sec-form-8-k-leadership-update-6061257)
- 2025-05-16 21:27 UTC [SEC Form NT 10-Q filed by Accelerate Diagnostics Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-accelerate-diagnostics-inc-6046157)
- 2025-05-12 20:16 UTC [SEC Form 8-K] [Accelerate Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/accelerate-diagnostics-inc-filed-sec-form-8-k-notice-of-delisting-6033283)
- 2025-05-08 20:05 UTC [SEC Form 8-K] [Accelerate Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/accelerate-diagnostics-inc-filed-sec-form-8-k-entry-into-a-6027256)
- 2025-05-08 13:00 UTC [Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets](https://www.quantisnow.com/insight/accelerate-diagnostics-files-for-chapter-11-protection-and-agrees-to-6026372)
- 2025-05-01 22:40 UTC [SEC Form 3] [SEC Form 3 filed by new insider Shalhoub Paul Vincent](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-shalhoub-paul-vincent-6014381)
- 2025-04-30 00:32 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by Accelerate Diagnostics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-accelerate-diagnostics-inc-6008487)
- 2025-04-25 21:25 UTC [SEC Form 8-K] [Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/accelerate-diagnostics-inc-filed-sec-form-8-k-leadership-update-6003318)
- 2025-04-15 21:25 UTC [SEC Form 8-K] [Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/accelerate-diagnostics-inc-filed-sec-form-8-k-leadership-update-5988992)
- 2025-04-07 23:34 UTC [SEC Form 4] [Chief Executive Officer Phillips Jack converted options into 53,283 shares and sold $16,473 worth of shares (25,343 units at $0.65), increasing direct ownership by 17% to 191,374 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-phillips-jack-converted-options-into-53283-shares-5980267)
- 2025-04-07 23:32 UTC [SEC Form 4] [Chief Technology Officer Mertz Larry Michael converted options into 4,298 shares and sold $990 worth of shares (1,523 units at $0.65), increasing direct ownership by 3% to 84,803 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-technology-officer-mertz-larry-michael-converted-options-into-4298-5980266)
- 2025-04-02 22:12 UTC [SEC Form 4] [Chief Financial Officer Patience David converted options into 20,000 shares and sold $4,839 worth of shares (6,816 units at $0.71), increasing direct ownership by 26% to 64,568 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-patience-david-converted-options-into-20000-shares-5973727)
- 2025-03-21 19:12 UTC [SEC Form 8-K] [Accelerate Diagnostics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/accelerate-diagnostics-inc-filed-sec-form-8-k-other-events-financial-5955708)
- 2025-03-21 17:52 UTC [Earnings Date] [Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance](https://www.quantisnow.com/insight/accelerate-diagnostics-submits-wave-system-and-gram-negative-positive-blood-culture-5955671)
- 2025-03-21 12:45 UTC [SEC Form 8-K] [Accelerate Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/accelerate-diagnostics-inc-filed-sec-form-8-k-results-of-operations-5955470)
- 2025-03-21 12:30 UTC [Earnings] [Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results](https://www.quantisnow.com/insight/accelerate-diagnostics-reports-fourth-quarter-and-full-year-2024-financial-results-5955449)
- 2025-03-21 01:55 UTC [SEC Form 10-K] [SEC Form 10-K filed by Accelerate Diagnostics Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-accelerate-diagnostics-inc-5955267)
- 2025-02-28 00:24 UTC [SEC Form 4] [Chief Financial Officer Patience David converted options into 1,500 shares and sold $583 worth of shares (535 units at $1.09), increasing direct ownership by 2% to 51,384 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-patience-david-converted-options-into-1500-shares-5915802)
- 2025-02-04 21:10 UTC [SEC Form 4] [Chief Executive Officer Phillips Jack converted options into 1,000 shares and sold $655 worth of shares (485 units at $1.35), increasing direct ownership by 0.32% to 163,434 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-phillips-jack-converted-options-into-1000-shares-5869953)
- 2025-01-30 00:45 UTC [SEC Form 8-K] [Accelerate Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/accelerate-diagnostics-inc-filed-sec-form-8-k-notice-of-delisting-5862414)
- 2025-01-10 21:14 UTC [SEC Form 8-K] [Accelerate Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/accelerate-diagnostics-inc-filed-sec-form-8-k-results-of-operations-5841949)
- 2025-01-10 21:05 UTC [Earnings Date] [Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results](https://www.quantisnow.com/insight/accelerate-diagnostics-announces-certain-preliminary-fourth-quarter-and-full-year-2024-5841820)
- 2024-12-05 22:13 UTC [SEC Schedule 13D] [Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13da-filed-by-accelerate-diagnostics-inc-5802500)
- 2024-12-04 01:48 UTC [Insider Buy] [Director Patience John bought $314,000 worth of shares (200,000 units at $1.57) (SEC Form 4)](https://www.quantisnow.com/insight/director-patience-john-bought-314000-worth-of-shares-200000-units-5799179)
- 2024-12-04 01:46 UTC [SEC Form 4] [Director Schuler Jack W sold $314,000 worth of shares (200,000 units at $1.57) (SEC Form 4)](https://www.quantisnow.com/insight/director-schuler-jack-w-sold-314000-worth-of-shares-200000-5799178)
- 2024-11-14 20:24 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Accelerate Diagnostics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-accelerate-diagnostics-inc-5775094)
- 2024-11-07 22:20 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Accelerate Diagnostics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-accelerate-diagnostics-inc-5760335)
- 2024-11-07 21:10 UTC [SEC Form 8-K] [Accelerate Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/accelerate-diagnostics-inc-filed-sec-form-8-k-results-of-operations-5759317)
- 2024-11-07 21:05 UTC [Earnings Date] [Accelerate Diagnostics Reports Third Quarter 2024 Financial Results](https://www.quantisnow.com/insight/accelerate-diagnostics-reports-third-quarter-2024-financial-results-5759054)
- 2024-10-25 20:30 UTC [Earnings Date] [Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results](https://www.quantisnow.com/insight/accelerate-diagnostics-scheduled-call-to-review-2024-third-quarter-results-5738752)
- 2024-09-30 13:15 UTC [SEC Form 8-K] [Accelerate Diagnostics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/accelerate-diagnostics-inc-filed-sec-form-8-k-other-events-financial-5708101)
- 2024-09-30 13:15 UTC [Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System](https://www.quantisnow.com/insight/accelerate-diagnostics-announces-fda-clearance-of-its-accelerate-arc-system-5708096)
- 2024-08-26 20:10 UTC [SEC Form 8-K] [Accelerate Diagnostics Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/accelerate-diagnostics-inc-filed-sec-form-8-k-other-events-5671878)
- 2024-08-12 21:01 UTC [SEC Schedule 13D] [Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13da-filed-by-accelerate-diagnostics-inc-5655338)
- 2024-08-08 21:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Accelerate Diagnostics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-accelerate-diagnostics-inc-5651625)
- 2024-08-08 20:05 UTC [Earnings Date] [Accelerate Diagnostics Reports Second Quarter 2024 Financial Results](https://www.quantisnow.com/insight/accelerate-diagnostics-reports-second-quarter-2024-financial-results-5650401)
- 2024-08-08 20:02 UTC [SEC Form 8-K] [Accelerate Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits](https://www.quantisnow.com/insight/accelerate-diagnostics-inc-filed-sec-form-8-k-entry-into-a-5650218)
- 2024-08-08 20:01 UTC [SEC Form 8-K] [Accelerate Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/accelerate-diagnostics-inc-filed-sec-form-8-k-results-of-operations-5650190)
- 2024-08-08 20:00 UTC [Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial](https://www.quantisnow.com/insight/accelerate-diagnostics-announces-a-successful-completion-of-its-wave-pre-clinical-5650115)
- 2024-08-08 15:09 UTC [Earnings Date] [Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results](https://www.quantisnow.com/insight/accelerate-diagnostics-scheduled-call-to-review-2024-second-quarter-results-5649804)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AXDX
- Earnings history: https://www.quantisnow.com/earnings/AXDX
- Dividend history: https://www.quantisnow.com/dividends/AXDX
- Insider transactions: https://www.quantisnow.com/insiders/AXDX
- Options chain: https://www.quantisnow.com/options/AXDX
- SEC 8-K filings only: https://www.quantisnow.com/company/AXDX/8-k
- RSS and alerts for AXDX: https://www.quantisnow.com/docs/rss-feeds.md